Search

Your search keyword '"Rannikko, Antti"' showing total 19 results
Start Over Author "Rannikko, Antti" Journal european urology
19 results on '"Rannikko, Antti"'

1. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer

Author

Englman, Cameron, Maffei, Davide, Allen, Clare, Kirkham, Alex, Albertsen, Peter, Kasivisvanathan, Veeru, Baroni, Ronaldo Hueb, Briganti, Alberto, De Visschere, Pieter, Dickinson, Louise, Gómez Rivas, Juan, Haider, Masoom A., Kesch, Claudia, Loeb, Stacy, Macura, Katarzyna J., Margolis, Daniel, Mitra, Anita M., Padhani, Anwar R., Panebianco, Valeria, Pinto, Peter A., Ploussard, Guillaume, Puech, Philippe, Purysko, Andrei S., Radtke, Jan Philipp, Rannikko, Antti, Rastinehad, Art, Renard-Penna, Raphaele, Sanguedolce, Francesco, Schimmöller, Lars, Schoots, Ivo G., Shariat, Shahrokh F., Schieda, Nicola, Tempany, Clare M., Turkbey, Baris, Valerio, Massimo, Villers, Arnauld, Walz, Jochen, Barrett, Tristan, Giganti, Francesco, and Moore, Caroline M.

Published
2024
Full Text
View/download PDF

2. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium

Author

Van Hemelrijck, Mieke, Ji, Xi, Helleman, Jozien, Roobol, Monique J, van der Linden, Wim, Nieboer, Daan, Bangma, Chris H, Frydenberg, Mark, Rannikko, Antti, Lee, Lui S, Gnanapragasam, Vincent J, Kattan, Mike W, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M, Gnanapragasam, Vincent, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, Obbink, Henk, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Zhang, Liying, Santa Olalla, Aida, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, La Pointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, and Bruinsma, Sophie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Aging, Prevention, Urologic Diseases, Cancer, Good Health and Well Being, Aged, Asia, Australia, Biopsy, Cause of Death, Clinical Decision-Making, Databases, Factual, Disease Progression, Early Detection of Cancer, Europe, Humans, Kallikreins, Male, Middle Aged, North America, Patient Dropouts, Predictive Value of Tests, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Assessment, Risk Factors, Time Factors, Watchful Waiting, Prostate cancer, Active surveillance, Discontinuation, Worldwide, Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium, Urology & Nephrology, Clinical sciences
Abstract

BackgroundCareful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa).ObjectiveUsing Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation.Design, setting, and participantsWe compared data from 10296 men on AS from 21 centres across 12 countries.Outcome measurements and statistical analysisCumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation.Results and limitationsDuring 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for

Published
2019

4. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts

Author

Drost, Frank-Jan H., primary, Nieboer, Daan, additional, Morgan, Todd M., additional, Carroll, Peter R., additional, Roobol, Monique J., additional, Trock, Bruce, additional, Ehdaie, Behfar, additional, Carroll, Peter, additional, Filson, Christopher, additional, Kim, Jeri, additional, Logothetis, Christopher, additional, Morgan, Todd, additional, Klotz, Laurence, additional, Pickles, Tom, additional, Hyndman, Eric, additional, Moore, Caroline M., additional, Gnanapragasam, Vincent, additional, Van Hemelrijck, Mieke, additional, Dasgupta, Prokar, additional, Bangma, Chris, additional, Roobol, Monique, additional, Villers, Arnauld, additional, Rannikko, Antti, additional, Perry, Antoinette, additional, Hugosson, Jonas, additional, Rubio-Briones, Jose, additional, Bjartell, Anders, additional, Hefermehl, Lukas, additional, Shiong, Lee Lui, additional, Frydenberg, Mark, additional, Kakehi, Yoshiyuki, additional, Chung, Byung Ha, additional, van der Kwast, Theo, additional, van der Linden, Wim, additional, Hulsen, Tim, additional, de Jonge, Cees, additional, Kattan, Mike, additional, Xinge, Ji, additional, Muir, Kenneth, additional, Lophatananon, Artitaya, additional, Fahey, Michael, additional, Steyerberg, Ewout, additional, Zhang, Liying, additional, Beckmann, Kerri, additional, Denton, Brian, additional, Hayen, Andrew, additional, Boutros, Paul, additional, Guo, Wei, additional, Benfante, Nicole, additional, Cowan, Janet, additional, Patil, Dattatraya, additional, Tolosa, Emily, additional, Kim, Tae-Kyung, additional, Mamedov, Alexandre, additional, LaPointe, Vincent, additional, Crump, Trafford, additional, Kimberly-Duffell, Jenna, additional, Santaolalla, Aida, additional, Olivier, Jonathan, additional, Rancati, Tiziana, additional, Ahlgren, Helén, additional, Mascarós, Juanma, additional, Löfgren, Annica, additional, Lehmann, Kurt, additional, Han Lin, Catherine, additional, Hirama, Hiromi, additional, Suk Lee, Kwang, additional, Jenster, Guido, additional, Auvinen, Anssi, additional, Haider, Masoom, additional, van Bochove, Kees, additional, Carter, Ballentine, additional, Gledhill, Sam, additional, Buzza, Mark, additional, Bruinsma, Sophie, additional, and Helleman, Jozien, additional

Published
2019
Full Text
View/download PDF

6. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force

Author

Moore, Caroline M., primary, Giganti, Francesco, additional, Albertsen, Peter, additional, Allen, Clare, additional, Bangma, Chris, additional, Briganti, Alberto, additional, Carroll, Peter, additional, Haider, Masoom, additional, Kasivisvanathan, Veeru, additional, Kirkham, Alex, additional, Klotz, Laurence, additional, Ouzzane, Adil, additional, Padhani, Anwar R., additional, Panebianco, Valeria, additional, Pinto, Peter, additional, Puech, Philippe, additional, Rannikko, Antti, additional, Renard-Penna, Raphaele, additional, Touijer, Karim, additional, Turkbey, Baris, additional, van Poppel, Heinrik, additional, Valdagni, Riccardo, additional, Walz, Jochen, additional, and Schoots, Ivo, additional

Published
2017
Full Text
View/download PDF

7. Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer

Author

Saeed, Khalid, primary, Rahkama, Vesa, additional, Eldfors, Samuli, additional, Bychkov, Dmitry, additional, Mpindi, John Patrick, additional, Yadav, Bhagwan, additional, Paavolainen, Lassi, additional, Aittokallio, Tero, additional, Heckman, Caroline, additional, Wennerberg, Krister, additional, Peehl, Donna M., additional, Horvath, Peter, additional, Mirtti, Tuomas, additional, Rannikko, Antti, additional, Kallioniemi, Olli, additional, Östling, Päivi, additional, and af Hällström, Taija M., additional

Published
2017
Full Text
View/download PDF

8. Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force

Author

Villa, Silvia, primary, Kendel, Friederike, additional, Venderbos, Lionne, additional, Rancati, Tiziana, additional, Bangma, Chris, additional, Carroll, Peter, additional, Denis, Louis, additional, Klotz, Laurence, additional, Korfage, Ida J., additional, Lane, Athene J., additional, Magnani, Tiziana, additional, Mastris, Ken, additional, Rannikko, Antti, additional, Roobol, Monique, additional, Trock, Bruce, additional, Van den Bergh, Roderick, additional, Van Poppel, Hendrik, additional, Valdagni, Riccardo, additional, and Bellardita, Lara, additional

Published
2017
Full Text
View/download PDF

12. Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study

Author

Bul, Meelan, primary, Zhu, Xiaoye, additional, Valdagni, Riccardo, additional, Pickles, Tom, additional, Kakehi, Yoshiyuki, additional, Rannikko, Antti, additional, Bjartell, Anders, additional, van der Schoot, Deric K., additional, Cornel, Erik B., additional, Conti, Giario N., additional, Boevé, Egbert R., additional, Staerman, Frédéric, additional, Vis-Maters, Jenneke J., additional, Vergunst, Henk, additional, Jaspars, Joris J., additional, Strölin, Petra, additional, van Muilekom, Erik, additional, Schröder, Fritz H., additional, Bangma, Chris H., additional, and Roobol, Monique J., additional

Published
2013
Full Text
View/download PDF

18. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force

Author

Jochen Walz, Baris Turkbey, Antti Rannikko, Clare Allen, Peter R. Carroll, Peter C. Albertsen, Alberto Briganti, Philippe Puech, Francesco Giganti, Peter A. Pinto, Anwar R. Padhani, Ivo G. Schoots, Caroline M. Moore, Masoom A. Haider, Laurence Klotz, Heinrik van Poppel, Alex Kirkham, Riccardo Valdagni, Veeru Kasivisvanathan, Valeria Panebianco, Adil Ouzzane, Raphaële Renard-Penna, Karim Touijer, Chris H. Bangma, Moore, Caroline M., Giganti, Francesco, Albertsen, Peter, Allen, Clare, Bangma, Chri, Briganti, Alberto, Carroll, Peter, Haider, Masoom, Kasivisvanathan, Veeru, Kirkham, Alex, Klotz, Laurence, Ouzzane, Adil, Padhani, Anwar R., Panebianco, Valeria, Pinto, Peter, Puech, Philippe, Rannikko, Antti, Renard-Penna, Raphaele, Touijer, Karim, Turkbey, Bari, van Poppel, Heinrik, Valdagni, Riccardo, Walz, Jochen, Schoots, Ivo, Urology, Radiology & Nuclear Medicine, Clinicum, Department of Surgery, Urologian yksikkö, and HUS Abdominal Center

Subjects
Male, medicine.medical_specialty, Consensus, Urology, Advisory Committees, 030232 urology & nephrology, Prostate MRI, Consensu, Active surveillance, Documentation, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, SDG 3 - Good Health and Well-being, medicine, Humans, Medical physics, Watchful Waiting, Case report form, Gynecology, prostate cancer, prostate MRI, advisory committees, consensus, documentation, Europe, humans, magnetic resonance imaging, male, oncology nursing, practice guidelines as topic, prostatic neoplasms, radiology, tumor burden, watchful waiting, Advisory Committee, Data collection, medicine.diagnostic_test, business.industry, Oncology Nursing, Cancer, Prostatic Neoplasms, Magnetic resonance imaging, medicine.disease, 3126 Surgery, anesthesiology, intensive care, radiology, Magnetic Resonance Imaging, Checklist, 3. Good health, Tumor Burden, 030220 oncology & carcinogenesis, Radiological weapon, Cohort, Practice Guidelines as Topic, Prostatic Neoplasm, business, FOLLOW-UP, Radiology, MRI, Human
Abstract

Background: Published data on prostate magnetic resonance imaging (MRI) during follow-up of men on active surveillance are lacking. Current guidelines for prostate MRI reporting concentrate on prostate cancer (PCa) detection and staging. A standardised approach to prostate MRI reporting for active surveillance will facilitate the robust collection of evidence in this newly developing area. Objective: To develop preliminary recommendations for reporting of individual MRI studies in men on active surveillance and for researchers reporting the outcomes of cohorts of men having MRI on active surveillance. Design, setting, and participants: The RAND/UCLA Appropriateness Method was used. Experts in urology, radiology, and radiation oncology developed a set of 394 statements relevant to prostate MRI reporting in men on active surveillance for PCa. Each statement was scored for agreement on a 9-point scale by each panellist prior to a panel meeting. Each statement was discussed and rescored at the meeting. Outcome measurements and statistical analysis: Measures of agreement and consensus were calculated for each statement. The most important statements, derived from both group discussion and scores of agreement and consensus, were used to create the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) checklist and case report form. Results and limitations: Key recommendations include reporting the index lesion size using absolute values at baseline and at each subsequent MRI. Radiologists should assess the likelihood of true change over time (ie, change in size or change in lesion characteristics on one or more sequences) on a 1-5 scale. A checklist of items for reporting a cohort of men on active surveillance was developed. These items were developed based on expert consensus in many areas in which data are lacking, and they are expected to develop and change as evidence is accrued. Conclusions: The PRECISE recommendations are designed to facilitate the development of a robust evidence database for documenting changes in prostateMRI findings over time ofmen on active surveillance. If used, they will facilitate data collection to distinguish-measurement error and natural variability in MRI appearances from true radiologic progression. Patient summary: Few published reports are available on how to use and interpret magnetic resonance imaging for men on active surveillance for prostate cancer. The PRECISE panel recommends that data should be collected in a standardised manner so that natural variation in the appearance and measurement of cancer over time can be distinguished from changes indicating significant tumour progression. (C) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results